Cite
Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.
MLA
Luckett, Kathleen A., et al. “Co-Inhibition of SMAD and MAPK Signaling Enhances 124I Uptake in BRAF-Mutant Thyroid Cancers.” Endocrine-Related Cancer, vol. 28, no. 6, June 2021, pp. 391–402. EBSCOhost, https://doi.org/10.1530/ERC-21-0017.
APA
Luckett, K. A., Cracchiolo, J. R., Krishnamoorthy, G. P., Leandro-Garcia, L. J., Nagarajah, J., Saqcena, M., Lester, R., Im, S. Y., Zhen Zhao, Lowe, S. W., de Stanchina, E., Sherman, E. J., Ho, A. L., Leach, S. D., Knauf, J. A., & Fagin, J. A. (2021). Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers. Endocrine-Related Cancer, 28(6), 391–402. https://doi.org/10.1530/ERC-21-0017
Chicago
Luckett, Kathleen A., Jennifer R. Cracchiolo, Gnana P. Krishnamoorthy, Luis Javier Leandro-Garcia, James Nagarajah, Mahesh Saqcena, Rona Lester, et al. 2021. “Co-Inhibition of SMAD and MAPK Signaling Enhances 124I Uptake in BRAF-Mutant Thyroid Cancers.” Endocrine-Related Cancer 28 (6): 391–402. doi:10.1530/ERC-21-0017.